Evaluation of the effects of felodipine, verapamil and hydralazine on the survival rate of rats subjected to lethal effects of oxygen free radicals.
Intravenous administration of xanthine (X: 0.225 mg/kg, i.v.) plus xanthine oxidase (XO: 3.0 units/kg, i.v.) to anesthetized rats resulted in a rapid fall in the arterial pressure and a mortality rate of over 80% during 120 min observation period. Pretreatment of the rats with superoxide dismutase (SOD) or SOD plus catalase significantly enhanced survival rate to 60% confirming that the toxicity after [X + XO] administration is due to the generation of oxygen free radicals. Pretreatment of the rats with either felodipine, a dihydropyridine calcium antagonist or verapamil, a structurally different Ca(2+)-channel blocker was most effective in promoting survival rate to 90%; in contrast, hydralazine, an arteriolar dilator but not a calcium antagonist, was ineffective in significantly enhancing survival. In the vehicle treated groups, mortality of the rats after [X + XO] administration was associated with significant increases in serum creatine phosphokinase (CPK) levels; both the calcium antagonists as well as hydralazine prevented any significant changes in CPK levels. Since only the calcium antagonists but not hydralazine were effective in providing significant protection against mortality, the data suggests that CPK may not be a reliable indicator to predict prevention of lethal toxicity induced by free radicals. Hence, the observation that calcium antagonists can promote survival would suggest that calcium overload may be the ultimate mediator of tissue toxicity. These observations can account for the remarkable efficacy of various calcium antagonists in preventing ischemia-reperfusion induced damage to organs, such as heart and kidneys, in which a role for free radicals has been postulated.
Jacinto
S M
SM
Department of Pharmacology, University of Houston, TX 77204-5515.
Jandhyala
B S
BS
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003402:Creatine Kinase / Q000097:blood; D015736:Felodipine / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006830:Hydralazine / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000627:therapeutic use*; D015996:Survival Rate; D014700:Verapamil / Q000627:therapeutic use*; D019820:Xanthine; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors / Q000633:toxicity*; D014970:Xanthines / Q000037:antagonists & inhibitors / Q000633:toxicity*
D014970:Xanthines; D019820:Xanthine; D006830:Hydralazine; D014700:Verapamil; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase; D003402:Creatine Kinase; D015736:Felodipine